{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:19:17Z","timestamp":1789913957711,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ijcard.2015.02.096","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T22:46:49Z","timestamp":1442875609000},"page":"3-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Mineralocorticoid receptor antagonists, a class beyond spironolactone \u2014 Focus on the special pharmacologic properties of eplerenone"],"prefix":"10.1016","volume":"200","author":[{"given":"Petar M.","family":"Seferovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pelliccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Zivkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsen","family":"Ristic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebojsa","family":"Lalic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Seferovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejan","family":"Simeunovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Milinkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2015.02.096_bb0005","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/01.HYP.37.3.845","article-title":"Arterial pressure, left ventricular mass, and aldosterone in essential hypertension","volume":"37","author":"El-Gharbawy","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2015.02.096_bb0010","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0015","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/CIRCULATIONAHA.106.668715","article-title":"Aldosterone and cardiovascular disease: smoke and fire","volume":"114","author":"Calhoun","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.02.096_bb0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"Sica","year":"2005","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1527-3466.2001.tb00064.x","article-title":"Eplerenone: a selective aldosterone receptor antagonist (SARA)","volume":"19","author":"Delyani","year":"2001","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0030","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1476-5381.2010.00750.x","article-title":"Renin\u2013angiotensin\u2013aldosterone system blockade for cardiovascular diseases: current status","volume":"160","author":"Ma","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/VHRM.S13779","article-title":"Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure","volume":"7","author":"Nappi","year":"2011","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0040","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","article-title":"Eplerenone: cardiovascular protection","volume":"107","author":"Brown","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.02.096_bb0045","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.02.096_bb0050","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0895-7061(97)00301-4","article-title":"Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension","volume":"10","author":"Blacher","year":"1997","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0055","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.02.096_bb0060","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.02.096_bb0065","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0070","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0075","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxyspirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0085","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ejheart.2005.11.008","article-title":"Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejections fraction \u226430%","volume":"8","author":"Pitt","year":"2006","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0090","author":"Center for Drug Evaluation and Research"},{"key":"10.1016\/j.ijcard.2015.02.096_bb0095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/IBPC.S13783","article-title":"Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine","volume":"6","author":"Funder","year":"2013","journal-title":"Integr. Blood Press. Control"},{"key":"10.1016\/j.ijcard.2015.02.096_bb0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0105","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1074248410371946","article-title":"Review article: eplerenone: an underused medication?","volume":"15","author":"Abuannadi","year":"2010","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0110","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s12072-010-9235-x","article-title":"Eplerenone reverses spironolactone-induced painful gynaecomastia in cirrhotics","volume":"5","author":"Dimitriadis","year":"2011","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.ijcard.2015.02.096_bb0115","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCHEARTFAILURE.112.000173","article-title":"Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study","volume":"6","author":"Krum","year":"2013","journal-title":"Circ. Heart Fail."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315002235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315002235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T18:55:51Z","timestamp":1748631351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527315002235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":23,"alternative-id":["S0167527315002235"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.02.096","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid receptor antagonists, a class beyond spironolactone \u2014 Focus on the special pharmacologic properties of eplerenone","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.02.096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}